Company intelligence / Profile preview

Arkios BioDevelopment

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Arkios Bio is a biotechnology company specializing in the development of next-generation viral vectors for gene therapy applications. Founded by gene therapy pioneer Katherine High and other former executives from Spark Therapeutics, the company focuses on optimizing Adeno-associated virus (AAV) capsids to enhance tissue targeting and reduce immunogenicity. In late 2023, the company was acquired by Alexion, the rare disease unit of AstraZeneca, to accelerate the development of genomic medicines. Arkios Bio's technology is designed to address the limitations of current gene delivery systems in treating rare genetic disorders.

Therapeutic areas: Rare Diseases
Modalities: Gene therapyAdeno-associated virus vector
Industry: Biotech

Beyond the preview

Go deeper on Arkios BioDevelopment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arkios BioDevelopment.

Explore the full profile